Haemonetics announced today that it entered into an agreement to acquire Attune Medical. Boston-based Haemonetics agreed to buy Attune for an upfront cash payment of $160 million. The deal also includes additional contingent consideration based on sales growth in the three years following the consummation of the acquisition. These additional payments also hinge on other […]
Haemonetics
Haemonetics completes $255M OpSens acquisition
Haemonetics announced today that it completed its previously announced acquisition of cardiology-focused medical device company OpSens. Boston-based Haemonetics first announced plans to buy OpSens for more than $250 million in October. Upon completion of the deal, the company acquired all outstanding shares at a fully diluted equity value of about $255 million. As a result, […]
Haemonetics to acquire OpSens for more than $250M, expanding cardiology device portfolio
Haemonetics today announced a definitive agreement to acquire cardiology-focused technology developer OpSens. Boston-based Haemonetics will acquire all outstanding shares of Opsens for CAD $2.90 in an all-cash transaction that will have a fully diluted equity value of approximately $253 million USD. The transaction is expected to close by the end of January 2024. Opsens develops […]
Haemonetics brings vascular closure device to Europe
Haemonetics (NYSE:HAE) today announced the first patients treated with its Vascade MVP venous vascular closure system in Germany. Boston-based Haemonetics said this marks the first use of the Vascade portfolio — widely used in the U.S. — in a European country. The company designed Vascade for small-bore femoral arterial and venous closure. Its general uses […]
FDA clears enhancements to plasma collection tech from Haemonetics
Haemonetics (NYSE:HAE) announced that the FDA cleared advancements to its NexSys PCS plasma collection system. Enhancements include a new plasma collection bowl and new Express Plus technology, according to a news release. The bowl features a patented design to optimize performance and Express Plus reduces procedure time. Boston-based Haemonetics designed NexSys PCS as a completely […]
FDA clears Haemonetics next-gen autotransfusion system software
Haemonetics (NYSE:HAE) announced today that it received FDA 510(k) clearance for next-generation software for the Cell Saver Elite+ autotransfusion system. Boston-based Haemonetics began a full market release for the software update, named Intelligent Control. It designed the software to offer key enhancements to simplify operations, support efficiency and improve user experience. Cell Saver Elite+ allows […]
The biggest medtech stock gainers, losers in 2022
In another roller coaster year for medtech, these are the companies that saw their stock rise and fall the most drastically. The MassDevice MedTech 100 Index, which includes stocks of the world’s largest medical device companies, reflects the performance of many in the medtech space. In a tough year for a lot of businesses, the Index […]
Haemonetics names Roy Galvin president of global plasma and blood center
Haemonetics (NYSE:HAE) announced today that it appointed Roy Galvin as president of its global plasma and blood center. Galvin’s position becomes effective Oct. 10, 2022. He will report to Haemonetics President and CEO Chris Simon. His responsibilities in the role include driving growth objectives and advancing the company’s leadership positions and innovation, according to a […]
Haemonetics stock rises on Street-beating Q1, raised guidance
Haemonetics (NYSE:HAE) shares ticked up before hours on first-quarter results that topped the consensus forecast. Shares of HAE were up 5.1% at $71 apiece before the market opened. They continued to rise and were up 7.8% at $72.84 in early-morning trading. The Boston-based hematology device company posted profits of $19.9 million, or 38¢ per share, […]
Haemonetics completes move to new Pennsylvania manufacturing facility
Haemonetics (NYSE:HAE) announced today that it fully commenced operations at its new manufacturing center in Clinton, Pennsylvania. Boston-based Haemonetics previously operated at a manufacturing plant in nearby Leetsdale, Pennsylvania, from 1990 until now. According to a news release, the custom-built facility constitutes approximately 200,000 square feet in Clinton Commerce Park near Pittsburgh International Airport. Initial […]
InnovHeart appoints former J&J executive as CEO
InnovHeart this week announced that it appointed medtech veteran David Wilson as CEO. Wilson has more than 30 years of experience in medical device industry. He previously served in numerous leadership roles at Johnson & Johnson, including worldwide president of Cordis. Wilson has also served at J&J as president of Mentor, VP of Ethicon R&D […]